|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TFAP4 |
Gene summary for TFAP4 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TFAP4 | Gene ID | 7023 |
| Gene name | transcription factor AP-4 | |
| Gene Alias | AP-4 | |
| Cytomap | 16p13.3 | |
| Gene Type | protein-coding | GO ID | GO:0000079 | UniProtAcc | Q01664 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 7023 | TFAP4 | LZE4T | Human | Esophagus | ESCC | 4.44e-07 | 2.13e-01 | 0.0811 |
| 7023 | TFAP4 | LZE7T | Human | Esophagus | ESCC | 3.34e-05 | 2.98e-01 | 0.0667 |
| 7023 | TFAP4 | LZE8T | Human | Esophagus | ESCC | 1.19e-04 | 1.48e-01 | 0.067 |
| 7023 | TFAP4 | LZE22T | Human | Esophagus | ESCC | 3.43e-02 | 2.32e-01 | 0.068 |
| 7023 | TFAP4 | LZE24T | Human | Esophagus | ESCC | 7.52e-12 | 3.66e-01 | 0.0596 |
| 7023 | TFAP4 | P1T-E | Human | Esophagus | ESCC | 9.00e-03 | 2.76e-01 | 0.0875 |
| 7023 | TFAP4 | P2T-E | Human | Esophagus | ESCC | 5.15e-44 | 8.04e-01 | 0.1177 |
| 7023 | TFAP4 | P4T-E | Human | Esophagus | ESCC | 9.58e-18 | 3.67e-01 | 0.1323 |
| 7023 | TFAP4 | P5T-E | Human | Esophagus | ESCC | 1.25e-24 | 3.73e-01 | 0.1327 |
| 7023 | TFAP4 | P8T-E | Human | Esophagus | ESCC | 5.98e-27 | 4.43e-01 | 0.0889 |
| 7023 | TFAP4 | P9T-E | Human | Esophagus | ESCC | 6.97e-12 | 2.59e-01 | 0.1131 |
| 7023 | TFAP4 | P10T-E | Human | Esophagus | ESCC | 3.14e-17 | 2.87e-01 | 0.116 |
| 7023 | TFAP4 | P11T-E | Human | Esophagus | ESCC | 1.26e-09 | 4.21e-01 | 0.1426 |
| 7023 | TFAP4 | P12T-E | Human | Esophagus | ESCC | 2.40e-35 | 6.20e-01 | 0.1122 |
| 7023 | TFAP4 | P15T-E | Human | Esophagus | ESCC | 6.93e-30 | 6.59e-01 | 0.1149 |
| 7023 | TFAP4 | P16T-E | Human | Esophagus | ESCC | 1.49e-27 | 4.10e-01 | 0.1153 |
| 7023 | TFAP4 | P17T-E | Human | Esophagus | ESCC | 1.16e-11 | 3.82e-01 | 0.1278 |
| 7023 | TFAP4 | P19T-E | Human | Esophagus | ESCC | 4.52e-04 | 6.78e-01 | 0.1662 |
| 7023 | TFAP4 | P20T-E | Human | Esophagus | ESCC | 3.56e-18 | 4.49e-01 | 0.1124 |
| 7023 | TFAP4 | P21T-E | Human | Esophagus | ESCC | 1.67e-34 | 6.99e-01 | 0.1617 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0016032111 | Esophagus | ESCC | viral process | 301/8552 | 415/18723 | 3.34e-29 | 1.32e-26 | 301 |
| GO:0051098111 | Esophagus | ESCC | regulation of binding | 251/8552 | 363/18723 | 6.73e-20 | 8.46e-18 | 251 |
| GO:0045862111 | Esophagus | ESCC | positive regulation of proteolysis | 256/8552 | 372/18723 | 7.88e-20 | 9.43e-18 | 256 |
| GO:004477216 | Esophagus | ESCC | mitotic cell cycle phase transition | 281/8552 | 424/18723 | 4.63e-18 | 4.45e-16 | 281 |
| GO:000734615 | Esophagus | ESCC | regulation of mitotic cell cycle | 293/8552 | 457/18723 | 8.00e-16 | 5.64e-14 | 293 |
| GO:001908017 | Esophagus | ESCC | viral gene expression | 80/8552 | 94/18723 | 2.04e-15 | 1.28e-13 | 80 |
| GO:0072331111 | Esophagus | ESCC | signal transduction by p53 class mediator | 121/8552 | 163/18723 | 9.61e-14 | 4.69e-12 | 121 |
| GO:0010563111 | Esophagus | ESCC | negative regulation of phosphorus metabolic process | 274/8552 | 442/18723 | 2.32e-12 | 9.41e-11 | 274 |
| GO:0045936111 | Esophagus | ESCC | negative regulation of phosphate metabolic process | 273/8552 | 441/18723 | 3.18e-12 | 1.25e-10 | 273 |
| GO:0051348111 | Esophagus | ESCC | negative regulation of transferase activity | 177/8552 | 268/18723 | 1.08e-11 | 4.00e-10 | 177 |
| GO:007190016 | Esophagus | ESCC | regulation of protein serine/threonine kinase activity | 227/8552 | 359/18723 | 1.12e-11 | 4.10e-10 | 227 |
| GO:2000116111 | Esophagus | ESCC | regulation of cysteine-type endopeptidase activity | 158/8552 | 235/18723 | 1.67e-11 | 5.90e-10 | 158 |
| GO:0043281111 | Esophagus | ESCC | regulation of cysteine-type endopeptidase activity involved in apoptotic process | 143/8552 | 209/18723 | 2.12e-11 | 7.31e-10 | 143 |
| GO:190198713 | Esophagus | ESCC | regulation of cell cycle phase transition | 242/8552 | 390/18723 | 3.86e-11 | 1.26e-09 | 242 |
| GO:190199013 | Esophagus | ESCC | regulation of mitotic cell cycle phase transition | 191/8552 | 299/18723 | 1.35e-10 | 3.94e-09 | 191 |
| GO:0044403111 | Esophagus | ESCC | biological process involved in symbiotic interaction | 186/8552 | 290/18723 | 1.43e-10 | 4.16e-09 | 186 |
| GO:0042326111 | Esophagus | ESCC | negative regulation of phosphorylation | 237/8552 | 385/18723 | 1.86e-10 | 5.33e-09 | 237 |
| GO:0001933111 | Esophagus | ESCC | negative regulation of protein phosphorylation | 213/8552 | 342/18723 | 3.54e-10 | 9.76e-09 | 213 |
| GO:00457865 | Esophagus | ESCC | negative regulation of cell cycle | 236/8552 | 385/18723 | 3.62e-10 | 9.93e-09 | 236 |
| GO:0010952111 | Esophagus | ESCC | positive regulation of peptidase activity | 133/8552 | 197/18723 | 4.31e-10 | 1.14e-08 | 133 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0520529 | Esophagus | ESCC | Proteoglycans in cancer | 138/4205 | 205/8465 | 1.79e-07 | 1.40e-06 | 7.15e-07 | 138 |
| hsa0520537 | Esophagus | ESCC | Proteoglycans in cancer | 138/4205 | 205/8465 | 1.79e-07 | 1.40e-06 | 7.15e-07 | 138 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| TFAP4 | PLA | Breast | ADJ | ZNF581,NUDT21,NIPSNAP2, etc. | 1.81e-01 |  |
| TFAP4 | PLA | Breast | DCIS | ZNF581,NUDT21,NIPSNAP2, etc. | 1.32e-01 |  |
| TFAP4 | PLA | Breast | Healthy | ZNF581,NUDT21,NIPSNAP2, etc. | 1.03e-01 |  |
| TFAP4 | PLA | Breast | IDC | ZNF581,NUDT21,NIPSNAP2, etc. | 1.39e-01 |  |
| TFAP4 | PLA | Breast | Precancer | ZNF581,NUDT21,NIPSNAP2, etc. | 1.23e-01 |  |
| TFAP4 | PLA | Colorectum | Healthy | ITGA6,TRIM5,COX15, etc. | 3.13e-01 |  |
| TFAP4 | MVA | Endometrium | AEH | IGFBP6,DKKL1,IFT80, etc. | 3.60e-02 |  |
| TFAP4 | PVA | Endometrium | EEC | IGFBP6,DKKL1,IFT80, etc. | 2.25e-01 |  |
| TFAP4 | NK | Esophagus | ESCC | MGME1,HS3ST3A1,ELOVL4, etc. | 7.20e-02 |  |
| TFAP4 | LYMEND | Esophagus | ADJ | PERP,ANKRD37,P2RY1, etc. | 1.43e-01 |  |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 2 3 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TFAP4 | SNV | Missense_Mutation | c.194N>G | p.Asn65Ser | p.N65S | Q01664 | protein_coding | deleterious(0.02) | probably_damaging(0.983) | TCGA-AN-A0AT-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| TFAP4 | SNV | Missense_Mutation | c.35N>T | p.Pro12Leu | p.P12L | Q01664 | protein_coding | deleterious_low_confidence(0.02) | probably_damaging(0.981) | TCGA-AO-A0J3-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cyclophosphamide | SD | |
| TFAP4 | SNV | Missense_Mutation | c.679N>T | p.Pro227Ser | p.P227S | Q01664 | protein_coding | tolerated(0.05) | benign(0.18) | TCGA-BH-A0HK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| TFAP4 | SNV | Missense_Mutation | c.385N>T | p.Arg129Trp | p.R129W | Q01664 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-BH-A1EX-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| TFAP4 | SNV | Missense_Mutation | novel | c.12N>G | p.Phe4Leu | p.F4L | Q01664 | protein_coding | tolerated_low_confidence(0.24) | possibly_damaging(0.827) | TCGA-PE-A5DE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
| TFAP4 | insertion | Nonsense_Mutation | novel | c.333_334insAAAAATTAGA | p.Gln112LysfsTer3 | p.Q112Kfs*3 | Q01664 | protein_coding | TCGA-A2-A0EQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
| TFAP4 | insertion | Frame_Shift_Ins | novel | c.114_115insAG | p.Glu39ArgfsTer83 | p.E39Rfs*83 | Q01664 | protein_coding | TCGA-B6-A0IK-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | ||
| TFAP4 | insertion | In_Frame_Ins | novel | c.113_114insTGACGT | p.Pro38_Glu39insAspVal | p.P38_E39insDV | Q01664 | protein_coding | TCGA-B6-A0IK-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | ||
| TFAP4 | SNV | Missense_Mutation | novel | c.583G>C | p.Val195Leu | p.V195L | Q01664 | protein_coding | tolerated(0.07) | benign(0.01) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| TFAP4 | SNV | Missense_Mutation | novel | c.368C>T | p.Ser123Leu | p.S123L | Q01664 | protein_coding | deleterious(0.02) | probably_damaging(0.953) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |